Utah Retirement Systems’s Ultragenyx Pharmaceutical RARE Stock Holding History

Utah Retirement Systems’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,800	Closed	-$202K	–	976
2024 Q4	$202K	Hold	4,800	–	–	﹤0.01%	956
2024 Q3	$267K	Buy	+4,800	New	+$245K	﹤0.01%	917
2024 Q2	–	Sell	-4,300	Closed	-$201K	–	994
2024 Q1	$201K	Hold	4,300	–	–	﹤0.01%	940
2023 Q4	$206K	Buy	+4,300	New	+$167K	﹤0.01%	956
2022 Q3	–	Sell	-3,400	Closed	-$203K	–	976
2022 Q2	$203K	Hold	3,400	–	–	﹤0.01%	960
2022 Q1	$247K	Hold	3,400	–	–	﹤0.01%	938
2021 Q4	$286K	Hold	3,400	–	–	﹤0.01%	922
2021 Q3	$307K	Buy	3,400 +100	+3%	+$9.04K	﹤0.01%	899
2021 Q2	$315K	Buy	+3,300	New	+$344K	﹤0.01%	904

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Utah Retirement Systems's RARE Position: Q1 2025 in Review

Utah Retirement Systems sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 4,800 shares — an estimated $202K sold.

Utah Retirement Systems first reported a position in RARE in Q2 2021 and held it in 9 quarters. The position peaked at $315K in Q2 2021. 299 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

Utah Retirement Systems reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Utah Retirement Systems sold 4,800 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $202K.
Utah Retirement Systems first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and held it in 9 quarters.
Utah Retirement Systems's Ultragenyx Pharmaceutical position peaked at $315K in Q2 2021.
299 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on Utah Retirement Systems's 13F filing for Q1 2025, filed 15 May 2025.